Pancreatic Cancer Is Cured? What This Means And What It Doesn't

Posted on 2026-02-25


With a relative five-year survival rate of only 13% across all stages, pancreatic cancer remains one of the deadliest malignancies. In the United States alone, the projected death toll in 2024 was more than 50,000 people (1). It is therefore unsurprising that when Liaki et al. published their study seemingly reporting a “cure” for pancreatic cancer in mouse models, it received widespread attention, making headlines across both scientific and mainstream media (2). But what does this study show and how excited should we really be?

A major obstacle thwarting the effective treatment of pancreatic cancer is the rapid development of resistance to therapeutics. In this preclinical study, published in PNAS, researchers aimed to overcome this by targeting the tumour on multiple fronts. Using three genetically engineered mouse models of pancreatic ductal adenocarcinoma (PDAC), they tested a novel drug combination which combined the use of a KRAS inhibitor (daraxonrasib), STAT3 protein degrader (SD36) and a drug already approved for lung adenocarcinoma (afatinib). The theory was simple yet powerful; it is more difficult for tumours to adapt to three simultaneous points of attack than to a single targeted therapy. 

Strikingly this approach proved highly effective in the models used. By attacking the tumour from 3 angles, they achieved complete tumour regression, with no signs of resistance emerging for the duration of the study. Histological analysis and imaging techniques proved the tumours to be undetectable, and the treated mice survived significantly longer than their untreated counterparts. Importantly, the therapy was well tolerated and resulted in no significant toxicities being observed. However, treatment was maintained throughout the study, meaning the effects following drug cessation remain unknown. Nonetheless, the results are an impressive demonstration of what this drug combination is capable of at this stage.  

Despite how exciting these findings are, it is essential to recognise that success in animal models does not automatically translate to effective treatment for human patients. Malignant pancreatic tumours in humans are incredibly genetically diverse, with a highly complex microenvironment (3). Replicating such conditions in different organisms is challenging at best. 

One example of this is desmoplasia; a dense fibrotic stroma characteristic of pancreatic cancer. Although genetically engineered mouse models can display fibrotic stroma resembling human disease, many preclinical systems still lack the full complexity of the tumour microenvironment, failing to capture the genomic diversity and systemic influences that shape pancreatic cancer in patients (4). This poses a significant obstacle for drug penetration and therefore has the potential to limit the efficacy of therapies that appear as strong contenders for “cures” in preclinical trials. It is important to note that encouragingly, pancreatic cancer models are getting better at reflecting the desmoplastic nature of human tumours, but for now these challenges remain.



 It is also difficult to conclude at this stage that the absence of adverse effects observed in mice would be mirrored in humans. Differences in metabolism, drug distribution and clearance, alongside the higher therapeutic dose which may be required to penetrate desmoplastic tissue, could result in toxicities occurring which were not observed in this study. This challenge is further compounded by the fact that pancreatic cancer is typically diagnosed at an advanced stage, by which point the tumour is well established in its treatment-resistant microenvironment. 

So how can these findings be translated from mice to medicine? The journey from preclinical discovery to an approved therapeutic is typically long and uncertain, with rigorous evaluation required at each stage. These findings, however, open the door to addressing critical unanswered questions, such as those surrounding the safety, toxicity, and ultimately the feasibility of translation to human patients. Next steps will likely include toxicity profiling, validation across a diverse range of animal models and, if results remain promising, progression to early-phase clinical trials. Even under ideal circumstances, this will likely take many years. 



Nevertheless, the significance of this study should not be understated. Few other preclinical investigations have been able to demonstrate the tumour regression and resistance prevention to the same degree. In doing so, this work has challenged the long-held assumption that resistance in these cases is inevitable. Whilst it does not yet represent a cure, its findings can be considered of equal importance. These results provide a feasible blueprint for how pancreatic cancer might be more effectively targeted and, particularly in this field, represents a monumental step forward.  

Proud to support cancer research, Abbexa’s catalogue features an extensive range of ELISA kits, antibodies and proteins, each tailored to meet the most specific requirements.


ELISA kitsAntibodiesProteins
Human Pancreatic Lipase (PNLIP) ELISA Kit (abx250913)Lipase, Pancreatic (PL) Antibody (abx173369)Human Lipase, Pancreatic (PL) Protein (abx654201)
Human Pancreatic Triacylglycerol Lipase (PNLIP) ELISA Kit (abx156730)Pancreatic Triacylglycerol Lipase (PNLIP) Antibody (abx028550)Pancreatic Polypeptide (abx166144)
Pig Serine Peptidase Inhibitor Kazal Type 1 (SPINK1) ELISA Kit (abx516821)Pancreatic Secretory Trypsin Inhibitor (SPINK1) Antibody (abx238180)Human Pancreatic Polypeptide (PPY) Peptide (OVA) (abx165589)
Pancreatic Polypeptide Receptor 1 (PPYR1) Antibody (abx027902)Pancreatic Polypeptide Receptor 1 (PPYR1) Antibody (abx027902)Mouse Lithostathine-1 (REG1A) Protein (abx166144)


References

1. American Cancer Society (2024). Cancer Facts & Figures 2024 (No. 500824). https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2024-cancer-facts-figures.html

2. Liaki, V., Barrambana, S., Kostopoulou, M., Lechuga, C. G., Zamorano-Dominguez, E., Acosta, D., Morales-Cacho, L., Álvarez, R., Sun, P., Rosas-Perez, B., Barrero, R., Jiménez-Parrado, S., López-García, A., San Roman, M., López-Gil, J. C., Drosten, M., Sainz, B., Jr, Musteanu, M., Caleiras, E., Dusetti, N., … Barbacid, M. (2025). A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Proceedings of the National Academy of Sciences of the United States of America, 122(49), e2523039122. https://doi.org/10.1073/pnas.2523039122

3. Pratticò, F., & Garajová, I. (2024). Focus on Pancreatic Cancer Microenvironment. Current oncology (Toronto, Ont.), 31(8), 4241–4260. https://doi.org/10.3390/curroncol31080316

4. Tesson, M., & Morton, J. P. (2024). The preclinical gap in pancreatic cancer and radiotherapy. Disease models & mechanisms, 17(7), dmm050703. https://doi.org/10.1242/dmm.050703

Written by Georgie Jackson